• Corporate Philosophy
  • Management Structure
  • Key Strengths
  • Current and Future

Vision

To become the most respected pharmaceutical company in India through Science and Innovation.

Mission

To become the leaders in the chosen therapeutic segments of Gynaecology, Infertility, Post Partum care and Luteal Support.

Core Values

  • Respect for individuals and ideas
  • Quality across all functions
  • Long term association with business partners
  • Profitable growth and value creation for all stakeholders
  • Need satisfaction for all customers

Shield  takes pride in calling itself a professionally driven company.   Shield is a privately held company with the founder entrepreneur, Mr.L.Mahadevan,  owning more than 50% of the shareholding. Chennai based private equity investor fund, M/s.Fulcrum Venture India has a significant stake in the business. The daily operations of the company are run by professionals from the industry, handpicked for their expertise in nurturing people, process and domain, three key pillars of the business. The business is ably advised by the board comprising members from the company, the PE Investor and the industry.

Key strength of Shield has been its in-house domain strength, its ability to access to scientific know-how and the ability to conceive marketable solutions that are unique and path-breaking.  The strategic think tank of Shield comprises a collective wisdom of 150 man- years of experience in the field of identifying and marketing pharmacological solutions. The product management team of Shield has been incubated and nurtured to identify solutions that are niche, holistic and scientifically advanced. Through constant engagement with KOLs (Key opinion leaders) and domain specialists in the country, Shield gains a deep insight into the healthcare needs of patients as well as care-givers. Shield also chooses and works with partners/agents, with a strong research background in order to identify and market Solutions that are path-breaking in these segments. Shield’s marketing campaigns are structured on the above to not only make them powerful but also scientifically insightful, creating a very high impact among the practicing medical community.

As of March 2016, Shield has its operations in 14 states across India.  Besides a strong presence in the four southern states, Shield has a vibrant presence in Central India, East and North East, Maharashtra and Delhi. Shield’s field force comprises 290 Medical Representatives ably supported by the managers. In FY ’17 Shield is poised to launch operations in 7 states thereby achieving a pan India presence.  Shield’s field force is expected to touch 500 Medical representatives in FY ’17 once key states such as Uttar Pradesh, West Bengal, Madhya Pradesh etc., are launched in the year.  Shield completed FY ’16 with a turnover of Rs.43.36 Crores (USD 4.67 Million), where 75% of its revenue is generated by the Gynaecology division, commenced in 2012.  The revenue is expected to grow at a CAGR of 32% in the next five years.  The legacy division, referred to as the ‘Dignity’ division, focuses on multivitamin and nutrition’s market, with a very specific bouquet of products that grows at a healthy 18 percentage.

About Us

Vision

To become the most respected pharmaceutical company in India through Science and Innovation.

Mission

To become the leaders in the chosen therapeutic segments of Gynaecology, Infertility, Post Partum care and Luteal Support.

Core Values

  • Respect for individuals and ideas
  • Quality across all functions
  • Long term association with business partners
  • Profitable growth and value creation for all stakeholders
  • Need satisfaction for all customers

Shield  takes pride in calling itself a professionally driven company.   Shield is a privately held company with the founder entrepreneur, Mr.L.Mahadevan,  owning more than 50% of the shareholding. Chennai based private equity investor fund, M/s.Fulcrum Venture India has a significant stake in the business. The daily operations of the company are run by professionals from the industry, handpicked for their expertise in nurturing people, process and domain, three key pillars of the business. The business is ably advised by the board comprising members from the company, the PE Investor and the industry.

Key strength of Shield has been its in-house domain strength, its ability to access to scientific know-how and the ability to conceive marketable solutions that are unique and path-breaking.  The strategic think tank of Shield comprises a collective wisdom of 150 man- years of experience in the field of identifying and marketing pharmacological solutions. The product management team of Shield has been incubated and nurtured to identify solutions that are niche, holistic and scientifically advanced. Through constant engagement with KOLs (Key opinion leaders) and domain specialists in the country, Shield gains a deep insight into the healthcare needs of patients as well as care-givers. Shield also chooses and works with partners/agents, with a strong research background in order to identify and market Solutions that are path-breaking in these segments. Shield’s marketing campaigns are structured on the above to not only make them powerful but also scientifically insightful, creating a very high impact among the practicing medical community.

As of March 2016, Shield has its operations in 14 states across India.  Besides a strong presence in the four southern states, Shield has a vibrant presence in Central India, East and North East, Maharashtra and Delhi. Shield’s field force comprises 290 Medical Representatives ably supported by the managers. In FY ’17 Shield is poised to launch operations in 7 states thereby achieving a pan India presence.  Shield’s field force is expected to touch 500 Medical representatives in FY ’17 once key states such as Uttar Pradesh, West Bengal, Madhya Pradesh etc., are launched in the year.  Shield completed FY ’16 with a turnover of Rs.43.36 Crores (USD 4.67 Million), where 75% of its revenue is generated by the Gynaecology division, commenced in 2012.  The revenue is expected to grow at a CAGR of 32% in the next five years.  The legacy division, referred to as the ‘Dignity’ division, focuses on multivitamin and nutrition’s market, with a very specific bouquet of products that grows at a healthy 18 percentage.

Corporate Philosophy

VISION

To become the most respected pharmaceutical company in India through Science and Innovation.

MISSION

To become the leaders in the chosen therapeutic segments of Gynaecology, Infertility, Post Partum care and Luteal Support.

CORE VALUES

  • Respect for individuals and ideas
  • Quality across all functions
  • Long term association with business partners
  • Profitable growth and value creation for all stakeholders
  • Need satisfaction for all customers

Management Structure

Shield  takes pride in calling itself a professionally driven company.   Shield is a privately held company with the founder entrepreneur, Mr.L.Mahadevan,  owning more than 50% of the shareholding. Chennai based private equity investor fund, M/s.Fulcrum Venture India has a significant stake in the business. The daily operations of the company are run by professionals from the industry, handpicked for their expertise in nurturing people, process and domain, three key pillars of the business. The business is ably advised by the board comprising members from the company, the PE Investor and the industry.

Key Strengths

Key strength of Shield has been its in-house domain strength, its ability to access to scientific know-how and the ability to conceive marketable solutions that are unique and path-breaking.  The strategic think tank of Shield comprises a collective wisdom of 150 man- years of experience in the field of identifying and marketing pharmacological solutions. The product management team of Shield has been incubated and nurtured to identify solutions that are niche, holistic and scientifically advanced. Through constant engagement with KOLs (Key opinion leaders) and domain specialists in the country, Shield gains a deep insight into the healthcare needs of patients as well as care-givers. Shield also chooses and works with partners/agents, with a strong research background in order to identify and market Solutions that are path-breaking in these segments. Shield’s marketing campaigns are structured on the above to not only make them powerful but also scientifically insightful, creating a very high impact among the practicing medical community.

Current And Future

As of March 2016, Shield has its operations in 14 states across India.  Besides a strong presence in the four southern states, Shield has a vibrant presence in Central India, East and North East, Maharashtra and Delhi. Shield’s field force comprises 290 Medical Representatives ably supported by the managers. In FY ’17 Shield is poised to launch operations in 7 states thereby achieving a pan India presence.  Shield’s field force is expected to touch 500 Medical representatives in FY ’17 once key states such as Uttar Pradesh, West Bengal, Madhya Pradesh etc., are launched in the year.  Shield completed FY ’16 with a turnover of Rs.43.36 Crores (USD 4.67 Million), where 75% of its revenue is generated by the Gynaecology division, commenced in 2012.  The revenue is expected to grow at a CAGR of 32% in the next five years.  The legacy division, referred to as the ‘Dignity’ division, focuses on multivitamin and nutrition’s market, with a very specific bouquet of products that grows at a healthy 18 percentage.

VISION

To become the most respected pharmaceutical company in India through Science and Innovation.

MISSION

To become the leaders in the chosen therapeutic segments of Gynaecology, Infertility, Post Partum care and Luteal Support.

CORE VALUES

  • Respect for individuals and ideas
  • Quality across all functions
  • Long term association with business partners
  • Profitable growth and value creation for all stakeholders
  • Need satisfaction for all customers

Shield takes pride in calling itself a professionally driven company. Shield is a privately held company with the founder entrepreneur, Mr.L.Mahadevan, owning more than 50% of the shareholding. Chennai based private equity investor fund, M/s.Fulcrum Venture India has a significant stake in the business. The daily operations of the company are run by professionals from the industry, handpicked for their expertise in nurturing people, process and domain, three key pillars of the business. The business is ably advised by the board comprising members from the company, the PE Investor and the industry.

Key strength of Shield has been its in-house domain strength, its ability to access to scientific know-how and the ability to conceive marketable solutions that are unique and path-breaking. The strategic think tank of Shield comprises a collective wisdom of 150 man- years of experience in the field of identifying and marketing pharmacological solutions. The product management team of Shield has been incubated and nurtured to identify solutions that are niche, holistic and scientifically advanced. Through constant engagement with KOLs (Key opinion leaders) and domain specialists in the country, Shield gains a deep insight into the healthcare needs of patients as well as care-givers. Shield also chooses and works with partners/agents, with a strong research background in order to identify and market Solutions that are path-breaking in these segments. Shields marketing campaigns are structured on the above to not only make them powerful but also scientifically insightful, creating a very high impact among the practicing medical community.

As of March 2016, Shield has its operations in 14 states across India. Besides a strong presence in the four southern states, Shield has a vibrant presence in Central India, East and North East, Maharashtra and Delhi. Shields field force comprises 290 Medical Representatives ably supported by the managers. In FY’17 Shield is poised to launch operations in 7 states thereby achieving a pan India presence. Shields field force is expected to touch 500 Medical representatives in FY’17 once key states such as Uttar Pradesh, West Bengal, Madhya Pradesh etc., are launched in the year. Shield completed FY’16 with a turnover of Rs.43.36 Crores (USD 4.67 Million), where 75% of its revenue is generated by the Gynaecology division, commenced in 2012. The revenue is expected to grow at a CAGR of 32% in the next five years. The legacy division, referred to as the ‘Dignity’ division, focuses on multivitamin and nutrition’s market, with a very specific bouquet of products that grows at a healthy 18 percentage.